LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...

The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its ...

Q3 2025 Earnings Call Transcript November 4, 2025 Corcept Therapeutics Incorporated misses on earnings expectations. Reported ...

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...

GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial ...

As of September 30, 2025, Corvus had cash, cash equivalents and marketable securities of $65.7 million as compared to $52.0 million as of December 31, 2024. Consistent with last quarter, Corvus ...